| Literature DB >> 30011274 |
Julia Guillebaud1, Barivola Bernardson1,2, Tsiry Hasina Randriambolamanantsoa1, Laurence Randrianasolo2, Jane Léa Randriamampionona2,3, Cesare Augusto Marino1, Voahangy Rasolofo4, Milijaona Randrianarivelojosia5, Ines Vigan-Womas6, Voula Stivaktas7, Marietjie Venter7, Patrice Piola2, Jean-Michel Héraud1.
Abstract
BACKGROUND: The increasing use of malaria diagnostic tests reveals a growing proportion of patients with fever but no malaria. Clinicians and health care workers in low-income countries have few tests to diagnose causes of fever other than malaria although several diseases share common symptoms. We propose here to assess etiologies of fever in Madagascar to ultimately improve management of febrile cases.Entities:
Mesh:
Year: 2018 PMID: 30011274 PMCID: PMC6062140 DOI: 10.1371/journal.pntd.0006642
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
Fig 1Map of Madagascar showing the 21 sentinel sites selected for the study.
[Source: This map was generated using a free source of public domain available at: http://www.maplibrary.org/library/stacks/Africa/Madagascar/index.htm].
Number of inclusions per site and age group.
| Sites of investigation | N | Age group | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| <5 y. | 5–14 y. | 15–24 y. | 25–49 y. | ≥50 y. | |||||||
| Antananarivo | 42 | 14 | 10 | 7 | 9 | 2 | |||||
| Farafangana | 39 | 13 | 10 | 10 | 5 | 1 | |||||
| Maintirano | 41 | 16 | 10 | 6 | 7 | 2 | |||||
| Nosy Be | 42 | 10 | 7 | 10 | 13 | 2 | |||||
| Ihosy | 41 | 24 | 6 | 4 | 6 | 1 | |||||
| Maroantsetra | 28 | 7 | 10 | 5 | 5 | 1 | |||||
| Ambatondrazaka | 30 | 10 | 10 | 5 | 3 | 2 | |||||
| Toamasina | 30 | 6 | 4 | 7 | 9 | 4 | |||||
| Mahajanga | 30 | 13 | 9 | 5 | 2 | 1 | |||||
| Maevatanana | 30 | 13 | 8 | 5 | 3 | 1 | |||||
| Antsiranana | 30 | 14 | 9 | 3 | 2 | 2 | |||||
| Tsiroanomandidy | 30 | 13 | 4 | 11 | 2 | 0 | |||||
| Ambositra | 30 | 11 | 11 | 4 | 4 | 0 | |||||
| Morondava | 30 | 22 | 7 | 0 | 1 | 0 | |||||
| Miandrivazo | 30 | 15 | 6 | 5 | 4 | 0 | |||||
| Mandritsara | 30 | 7 | 11 | 8 | 3 | 1 | |||||
| Antsohihy | 30 | 14 | 9 | 4 | 3 | 0 | |||||
| Toliara | 30 | 12 | 2 | 8 | 7 | 1 | |||||
| Sambava | 30 | 7 | 8 | 9 | 6 | 0 | |||||
| Taolagnaro | 30 | 15 | 6 | 2 | 7 | 0 | |||||
| Moramanga | 29 | 11 | 7 | 4 | 7 | 0 | |||||
Fig 2Proportions of diseases under surveillance within the FSSN according to their respective case definition.
*p-value <0.05.
Distribution of groups of infection and pathogens detected among febrile patients (N = 682).
| Pathogens | Overall | <5 years n = 266 (%) | 5–14 years | 15–24 years | 25–49 years | ≥50 |
|---|---|---|---|---|---|---|
| No pathogen detected | 406 (59.5) | 148 (55.6) | 91 (55.8) | 76 (61.3) | 78 (72.2) | 13 (61.9) |
| Malaria (RDT) | 116 (17.0) | 32 (12.0) | 38 (23.3) | 28 (22.6) | 13 (12.0) | 5 (23.8) |
| Virus infections | 181 (26.5) | 97 (36.5) | 42 (25.8) | 21 (16.9) | 17 (15.8) | 4 (19.1) |
| HRV | 59 (8.7) | 31 (11.7) | 12 (7.4) | 11 (8.9) | 5 (4.6) | - |
| IAV/IBV | 57 (8.4) | 18 (6.8) | 21 (12.9) | 11 (8.9) | 6 (5.6) | 1 (4.8) |
| EBV | 44 (6.5) | 29 (10.9) | 6 (3.7) | 1 (0.8) | 4 (3.7) | 4 (19.1) |
| RSV | 26 (3.8) | 22 (8.3) | 4 (2.5) | - | - | - |
| HBV | 6 (0.9) | 1 (0.4) | 2 (1.2) | 1 (0.8) | 2 (1.9) | - |
| AdV | 2 (0.3) | 2 (0.8) | - | - | - | - |
| CMV | 1 (0.2) | 1 (0.4) | - | - | - | - |
| HAV | 1 (0.2) | - | - | - | 1 (0.9) | - |
| RVFV | 1 (0.2) | - | 1 (0.6) | - | - | - |
| VZV | 1 (0.2) | 1 (0.4) | - | - | - | - |
| HIV | 1 (0.2)3 | - | - | - | 1 (1.1)3 | - |
| Bacterial infections | 7 (1.0) | 1 (0.4) | 1 (0.6) | 1 (0.8) | 3 (2.8) | 1 (4.8) |
| | 4 (0.6) | - | - | - | 3 (2.8) | 1 (4.8) |
| | 1 (0.2) | - | - | 1 (0.8) | - | - |
| | 2 (0.3) | 1 (0.4) | 1 (0.6) | - | - | - |
Abbreviations: RDT = Rapid diagnostic Test; HRV = Human Rhinoviruses; IAV/IBV = Influenza viruses A and B; EBV = Epstein-Barr virus; RSV = Respiratory Syncytial Virus; HBV = Hepatitis B virus; ADV = Adenovirus; CMV = Cytomegalovirus; HAV = Hepatitis A virus; RVFV = Rift Valley Fever virus; VZV = Varicella Zoster virus; HIV = Human Immunodeficiency virus.
1 HRV, IAV/IVB and RSV were detected from respiratory specimens. EBV, HBV, ADV, CMV, HAV, RVFV and VZV were detected from blood specimens.
2 We only tested patient presenting with cough (n = 23) assuming that patients without cough are non-tuberculosis cases.
3 Due to unavailability of rapid test for HIV at the beginning of the study, patients in Antananarivo couldn’t be screened for HIV; A total of 15 patients refused HIV screening. Thus we screened 625 patients including 91 adults aged 25–49 years for HIV and this number was taken as denominator in the calculation of the positivity rate.
* p-value<0.05
Distribution of infection detected per syndrome/disease under surveillance within the Fever Sentinel Surveillance Network.
| Fever Sentinel Surveillance Network | |||||
|---|---|---|---|---|---|
| ILI (n = 319) | Malaria (n = 116) | DLS (n = 95) | Diarrhea (n = 76) | Other (n = 155) | |
| 95 (29.8%) | 1 (0.9%) | 6 (6.9%) | 2 (2.6%) | 6 (3.4%) | |
| 31 (9.7%) | 12 (10.3%) | 4 (4.2%) | 9 (11.8%) | 12 (7.7%) | |
| 24 (7.5%) | 2 (1.7%) | - | 6 (7.9%) | - | |
| 26 (8.2%) | - | - | 3 (4.0%) | - | |
| 23 (7.2%) | 12 (10.3%) | 3 (3.2%) | 7 (9.2%) | 5 (3.2%) | |
| - | 4 (3.4%) | 1 (1.1%) | - | - | |
| - | - | - | - | 1 (0.6%) | |
| 2 (0.6%) | - | - | - | - | |
| 1 (0.3%) | - | - | 1 (1.3%) | - | |
| 1 (0.3%) | - | - | 1 (1.3%) | - | |
| - | - | - | - | 1 (0.6%) | |
| - | - | - | - | 1 (0.6%) | |
| - | - | - | - | 1 (0.6% | |
| - | - | 1 (1.1%) | - | - | |
| 3 (0.9%) | - | - | - | 1 (0.6%) | |
Abbreviation: IAV/IBV = Influenza viruses A and B; HRV = Human Rhinoviruses; RSV = Respiratory Syncytial Virus; EBV = Epstein-Barr virus; HBV = Hepatitis B virus; HAV = Hepatitis A virus; ADV = Adenovirus; CMV = Cytomegalovirus; VZV = Varicella Zoster virus; RVFV = Rift Valley Fever virus; HIV = Human Immunodeficiency virus.